| 1. |
- Leijon, Mats, et al.
(author)
-
Wave Energy from the North Sea : Experiences from the Lysekil Research Site
- 2008
-
In: Surveys in geophysics. - : Springer Science and Business Media LLC. - 0169-3298 .- 1573-0956. ; 29:3, s. 221-240
-
Research review (peer-reviewed)abstract
- This paper provides a status update on the development of the Swedish wave energy research area located close to Lysekil on the Swedish West coast. The Lysekil project is run by the Centre for Renewable Electric Energy Conversion at Uppsala University. The project was started in 2004 and currently has permission to run until the end of 2013. During this time period 10 grid-connected wave energy converters, 30 buoys for studies on environmental impact, and a surveillance tower for monitoring the interaction between waves and converters will be installed and studied. To date the research area holds one complete wave energy converter connected to a measuring station on shore via a sea cable, a Wave Rider™ buoy for wave measurements, 25 buoys for studies on environmental impact, and a surveillance tower. The wave energy converter is based on a linear synchronous generator which is placed on the sea bed and driven by a heaving point absorber at the ocean surface. The converter is directly driven, i.e. it has no gearbox or other mechanical or hydraulic conversion system. This results in a simple and robust mechanical system, but also in a somewhat more complicated electrical system.
|
|
| 2. |
- Nilsson, Per J, et al.
(author)
-
Epidermoid anal cancer : a review of a population-based series of 308 consecutive patients treated according to prospective protocols
- 2005
-
In: International Journal of Radiation Oncology, Biology, Physics. - New York, USA : Elsevier. - 0360-3016 .- 1879-355X. ; 61, s. 92-102
-
Research review (peer-reviewed)abstract
- Purpose: The primary therapy in epidermoid anal cancer is radiotherapy, generally with chemotherapy. The use of neoadjuvant chemotherapy has been infrequently reported in the literature. This study presents results from a large population-based series and provides comparisons between different treatments.Methods and materials: Between 1985 and 2000, 308 patients with invasive epidermoid anal cancer were diagnosed in the Stockholm Health Care Region. Treatment was given according to defined protocols. External beam radiotherapy alone or with concomitant bleomycin and neoadjuvant chemotherapy followed by radiotherapy alone were the primary treatments. Radical surgery was reserved for poor responders or recurrences. Data were reviewed with regard to treatment, outcome, and prognostic factors.Results: Among the 276 patients (90%) treated with curative intent, 264 (96%) received treatment in accordance with the protocols. The overall 5-year survival rate was 68%. Among the 142 patients with locally advanced tumors (T > or =4 cm or N+), patients treated with neoadjuvant platinum-based chemotherapy (n = 91) had significantly better complete response rates compared with patients treated with radiotherapy with or without bleomycin (n = 51) (92% vs. 76%, p < 0.01). A significantly increased overall 5-year survival rate was also found among patients receiving neoadjuvant therapy (63% vs. 44%, p < 0.05).Conclusion: Structured treatment protocols result in favorable outcome on a population level. The results further suggest a significant therapeutic gain from including neoadjuvant chemotherapy in the treatment of locally advanced anal cancer.
|
|
| 3. |
- Ohlsson, Claes, 1965, et al.
(author)
-
The role of liver-derived insulin-like growth factor-I.
- 2009
-
In: Endocrine reviews. - : The Endocrine Society. - 1945-7189 .- 0163-769X. ; 30:5, s. 494-535
-
Research review (peer-reviewed)abstract
- IGF-I is expressed in virtually every tissue of the body, but with much higher expression in the liver than in any other tissue. Studies using mice with liver-specific IGF-I knockout have demonstrated that liver-derived IGF-I, constituting a major part of circulating IGF-I, is an important endocrine factor involved in a variety of physiological and pathological processes. Detailed studies comparing the impact of liver-derived IGF-I and local bone-derived IGF-I demonstrate that both sources of IGF-I can stimulate longitudinal bone growth. We propose here that liver-derived circulating IGF-I and local bone-derived IGF-I to some extent have overlapping growth-promoting effects and might have the capacity to replace each other (= redundancy) in the maintenance of normal longitudinal bone growth. Importantly, and in contrast to the regulation of longitudinal bone growth, locally derived IGF-I cannot replace (= lack of redundancy) liver-derived IGF-I for the regulation of a large number of other parameters including GH secretion, cortical bone mass, kidney size, prostate size, peripheral vascular resistance, spatial memory, sodium retention, insulin sensitivity, liver size, sexually dimorphic liver functions, and progression of some tumors. It is clear that a major role of liver-derived IGF-I is to regulate GH secretion and that some, but not all, of the phenotypes in the liver-specific IGF-I knockout mice are indirect, mediated via the elevated GH levels. All of the described multiple endocrine effects of liver-derived IGF-I should be considered in the development of possible novel treatment strategies aimed at increasing or reducing endocrine IGF-I activity.
|
|
